News
-
-
COMMUNIQUÉ DE PRESSE
Gemina Labs Announces Addition to its IP Portfolio
Gemina Laboratories Ltd. announces licensing of novel biosensing architecture from the University of British Columbia. The technology enables affordable high-sensitivity molecular diagnostics for infections like Mycobacterium tuberculosis -
-
-
COMMUNIQUÉ DE PRESSE
Gemina Laboratories Sign First Strategic License Agreement
Gemina Laboratories Ltd. announces license agreement with global diagnostics company, validating its technology in the in vitro diagnostics market. CEO Brian Firth highlights cost-saving potential and future partnerships -
-
-
COMMUNIQUÉ DE PRESSE
Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships
Gemina Laboratories Ltd shares strategic update for 2024, focusing on revenue streams, partnerships, and new technologies for diagnostics. Company plans new protein production facility and market expansion -
-